Yıl: 2024 Cilt: 44 Sayı: 1 Sayfa Aralığı: 43 - 52 Metin Dili: İngilizce DOI: 10.5336/medsci.2023-97930 İndeks Tarihi: 10-06-2024

A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease

Öz:
The global spread of the severe acute respiratory syn- drome-coronavirus-2 (SARS-CoV-2) virus has led to a widespread out- break of coronavirus disease-2019 (COVID-19), resulting in a pandemic. Following the end of the pandemic, COVID-19 has transi- tioned into an endemic phase characterized by anticipated periodic surges. Therefore, the development of readily available prognostic biomarkers for COVID-19 patients continues to be a crucial field of study. Monitoring of blood biomarkers for patients with COVID-19 is a crucial component of patient care. Therefore, it is necessary to con- duct hematological assessments such as leukocyte count, lymphocyte count, neutrophil count, neutrophil-lymphocyte ratio, and thrombocyte count. Additionally, inflammatory markers such as C-reactive protein, erythrocyte sedimentation rate, and procalcitonin should be measured. Immunological indicators including interleukin-6 and tumor necrosis factor-α should also be evaluated. Furthermore, biochemical tests such as aspartate aminotransferase, alanine aminotransferase, urea, creati- nine, and troponin levels should be assessed. Lastly, coagulation pa- rameters such as D-dimer, fibrin degradation products, and fibrin levels should also be examined. The objective of this narrative review is to as- sess blood biomarkers that have the potential to be valuable in moni- toring the progression and management of COVID-19. Studies published between 2020 and 2023 and scanned in PubMed, Ebsco and Google Scholar were used in the analysis. Keywords such as “COVID- 19”, “SARS-CoV2”, “biomarkers” and “severe SARS-CoV-2 infec- tion” were used to restrict the search.
Anahtar Kelime: COVID-19 SARS-CoV-2 biomarkers

COVID-19 Hastalarında Hastalığın Seyrini Gösteren Biyobelirteçlerin Değerlendirilmesine İlişkin Anlatısal Bir İnceleme

Öz:
Şiddetli akut solunum sendromu-koronavirüs-2 [severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)] virüsünün kü- resel yayılımı, yaygın bir koronavirüs hastalığı-2019 [coronavirus di- sease-2019 (COVID-19)] salg ınına yol açarak bir pandemiye yol açmıştır. Pandeminin sona ermesinin ardından, COVID-19, beklenen periyodik artışlarla karakterize edilen endemik bir a şamaya geçmiş- tir. Bu nedenle, COVID-19 hastaları için kolaylıkla bulunabilen prog- nostik biyobelirteçlerin geliştirilmesi önemli bir çalışma alanı olmaya devam etmektedir. COVID-19 hastalar ına yönelik kan biyobelirteç- lerinin izlenmesi hasta bak ımının çok önemli bir parças ıdır. Bu ne- denle lökosit say ısı, lenfosit say ısı, nötrofil say ısı, nötrofil-lenfosit oranı, trombosit say ısı gibi hematolojik de ğerlendirmeler; C-reaktif protein, eritrosit sedimantasyon hızı ve prokalsitonin gibi inflamatuar belirteçler; interlökin-6 ve tümör nekroz faktörü-α gibi immünolojik göstergeler değerlendirilmelidir. Ayrıca aspartat aminotransferaz, ala- nin aminotransferaz, üre, kreatinin ve troponin düzeyleri gibi biyo- kimyasal testler; D-dimer, fibrin bozunma ürünleri, fibrin düzeyleri gibi pıhtılaşma parametreleri incelenmelidir. Bu geleneksel derleme- nin amacı, COVID-19 hastal ığının ve tedavisinin monitörizasyonu için faydalanabilecek kan biyobelirteçlerini değerlendirmektir. Ana- lizde 2020 ile 2023 yılları arasında yayımlanan ve PubMed, Ebsco ve Google Scholar’da taranan çal ışmalar kullanılmıştır. Aramayı kısıt- layabilmek için “COVID-19”, “SARS-CoV2”, “biyobelirteçler” ve “şiddetli SARS-CoV2 enfeksiyonu” gibi anahtar kelimeler kullan ıl- mıştır.
Anahtar Kelime: COVID-19 SARS-CoV-2 biyobelirteçler

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
0
0
0
  • 1. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47. [Crossref] [PubMed] [PMC]
  • 2. Karimi Shahri M, Niazkar HR, Rad F. COVID-19 and hematology findings based on the current evidences: A puzzle with many missing pieces. Int J Lab Hematol. 2021;43(2):160-8. [Crossref] [PubMed] [PMC]
  • 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, uK. COVID-19: consider cytokine storm syn- dromes and immunosuppression. Lancet. 2020;395(10229):1033-4. [Cross- ref] [PubMed] [PMC]
  • 4. Mittal R, Chourasia N, Bharti VK, Singh S, Sarkar P, Agrawal A, et al. Blood- based biomarkers for diagnosis, prognosis, and severity prediction of COVID- 19: Opportunities and challenges. J Family Med Prim Care. 2022;11(8):4330-41. [Crossref] [PubMed] [PMC]
  • 5. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi- organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. [Crossref] [PubMed] [PMC]
  • 6. Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological pre- dictor of outcomes in COVID-19 patients: a nationwide cohort study. Cancers (Basel). 2021;13(3):471. [Crossref] [PubMed] [PMC]
  • 7. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis. 2020;96:131-5. [Cross- ref] [PubMed] [PMC]
  • 8. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. Erratum in: Signal Transduct Tar- get Ther. 2020;5(1):61. [Crossref] [PubMed] [PMC]
  • 9. Chan SSW, Christopher D, Tan GB, Chong VCL, Fan BE, Lin CY, et al. Pe- ripheral lymphocyte subset alterations in COVID-19 patients. Int J Lab Hema- tol. 2020;42(5):e199-e203. [Crossref] [PubMed] [PMC]
  • 10. Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia dur- ing the COVID-19 infection: What it shows and what can be learned. Immunol Lett. 2020;225:31-32. [Crossref] [PubMed] [PMC]
  • 11. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694-703. [Crossref] [PubMed] [PMC]
  • 12. Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID- 19: A cross-sectional study of 148 patients. Diabetes Metab Syndr. 2020;14(6):2099-102. [Crossref] [PubMed] [PMC]
  • 13. Pozdnyakova O, Connell NT, Battinelli EM, Connors JM, Fell G, Kim AS. Clin- ical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. Am J Clin Pathol. 2021;155(3):364-75.[Cross- ref] [PubMed] [PMC]
  • 14. Dubey DB, Mishra S, Reddy HD, Rizvi A, Ali W. Hematological and serum biochemistry parameters as a prognostic indicator of severally ill versus mild Covid-19 patients: A study from tertiary hospital in North India. Clin Epidemiol Glob Health. 2021;12:100806. [Crossref] [PubMed] [PMC]
  • 15. Cavalcante-Silva LHA, Carvalho DCM, Lima ÉA, Galvão JGFM, da Silva JSF, Sales-Neto JM, et al. Neutrophils and COVID-19: The road so far. Int Im- munopharmacol. 2021;90:107233. [Crossref] [PubMed] [PMC]
  • 16. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8. [Crossref] [PubMed] [PMC]
  • 17. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et al. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflamma- tion-related phenotypic changes in peripheral blood monocytes. J Leukoc Biol. 2021;109(1):13-22. [Crossref] [PubMed] [PMC]
  • 18. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355- 62. Erratum in: Nat Rev Immunol. 2020. [Crossref] [PubMed] [PMC]
  • 19. Naoum FA, Ruiz ALZ, Martin FHO, Brito THG, Hassem V, Oliveira MGL. Di- agnostic and prognostic utility of WBC counts and cell population data in pa- tients with COVID-19. Int J Lab Hematol. 2021;43 Suppl 1(Suppl 1):124-8. [Crossref] [PubMed] [PMC]
  • 20. Roca E, Ventura L, Zattra CM, Lombardi C. EOSINOPENIA: an early, effec- tive and relevant COVID-19 biomarker? QJM. 2021;114(1):68-9. [Crossref] [PubMed] [PMC]
  • 21. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469-72. [Crossref] [PubMed] [PMC]
  • 22. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8. [Crossref] [PubMed] [PMC]
  • 23. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-8. [Crossref] [PubMed] [PMC]
  • 24. Pan Y, Ye G, Zeng X, Liu G, Zeng X, Jiang X, et al. Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia? Clin Transl Med. 2020;10(1):161-8. [Cross- ref] [PubMed] [PMC]
  • 25. Russo A, Tellone E, Barreca D, Ficarra S, Laganà G. Implication of COVID- 19 on erythrocytes functionality: red blood cell biochemical implications and morpho-functional aspects. Int J Mol Sci. 2022;23(4):2171. [Crossref] [PubMed] [PMC]
  • 26. Fei Y, Tang N, Liu H, Cao W. Coagulation dysfunction. Arch Pathol Lab Med. 2020;144(10):1223-9. [Crossref] [PubMed]
  • 27. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761. [Crossref] [PubMed] [PMC]
  • 28. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associ- ated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. [Crossref] [PubMed] [PMC]
  • 29. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. [Cross- ref] [PubMed] [PMC]
  • 30. Aboughdir M, Kirwin T, Abdul Khader A, Wang B. Prognostic value of cardio- vascular biomarkers in COVID-19: a review. Viruses. 2020;12(5):527. [Cross- ref] [PubMed] [PMC]
  • 31. Gacche RN, Gacche RA, Chen J, Li H, Li G. Predictors of morbidity and mor- tality in COVID-19. Eur Rev Med Pharmacol Sci. 2021;25(3):1684-707. [PubMed]
  • 32. Ceci FM, Ferraguti G, Lucarelli M, Angeloni A, Bonci E, Petrella C, et al. In- vestigating biomarkers for COVID-19 morbidity and mortality. Curr Top Med Chem. 2023;23(13):1196-210. [Crossref] [PubMed]
  • 33. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med. 2020;58(7):1037-52. [Crossref] [PubMed]
  • 34. Mosquera-Sulbaran JA, Pedreañez A, Carrero Y, Callejas D. C-reactive pro- tein as an effector molecule in Covid-19 pathogenesis. Rev Med Virol. 2021;31(6):e2221. [Crossref] [PubMed] [PMC]
  • 35. Gogate N, Lyman D, Bell A, Cauley E, Crandall KA, Joseph A, et al. COVID- 19 biomarkers and their overlap with comorbidities in a disease biomarker data model. Brief Bioinform. 2021;22(6):bbab191. [Crossref] [PubMed] [PMC]
  • 36. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332-4. [Crossref] [PubMed] [PMC]
  • 37. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270-9. [Crossref] [PubMed] [PMC]
  • 38. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 2021;13(1):5. [Crossref] [PubMed] [PMC]
  • 39. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al; COPE Study Collaborators. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420-9. [Crossref] [PubMed] [PMC]
  • 40. Ahmed S, Jafri L, Hoodbhoy Z, Siddiqui I. Prognostic value of serum procal- citonin in COVID-19 Patients: a systematic review. Indian J Crit Care Med. 2021;25(1):77-84. [Crossref] [PubMed] [PMC]
  • 41. Yuan X, Huang W, Ye B, Chen C, Huang R, Wu F, et al. Changes of hema- tological and immunological parameters in COVID-19 patients. Int J Hema- tol. 2020;112(4):553-9. [Crossref] [PubMed] [PMC]
  • 42. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta. 2020;510:475- 82. [Crossref] [PubMed] [PMC]
  • 43. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401-9. [Crossref] [PubMed] [PMC]
  • 44. Kaya T, Nalbant A, Kılıçcıoğlu GK, Çayır KT, Yaylacı S, Varım C. The prog- nostic significance of erythrocyte sedimentation rate in COVID-19. Rev Assoc Med Bras (1992). 2021;67(9):1305-10. [Crossref] [PubMed]
  • 45. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-43. [Crossref] [PubMed] [PMC]
  • 46. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Pre- dictors of COVID-19 severity: A literature review. Rev Med Virol. 2021;31(1):1- 10. [Crossref] [PubMed] [PMC]
  • 47. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. El- evated troponin in patients with coronavirus disease 2019: possible mecha- nisms. J Card Fail. 2020;26(6):470-5. [Crossref] [PubMed] [PMC]
  • 48. Kaufmann CC, Ahmed A, Burger AL, Muthspiel M, Jäger B, Wojta J, et al. Biomarkers associated with cardiovascular disease in COVID-19. Cells. 2022;11(6):922. [Crossref] [PubMed] [PMC]
  • 49. Güney T, Karataş A. Hepatoloji. Anılır E, Önal Z, İbrişim D, editörler. Karaciğer Fonksiyon Testleri ve Güncel Geli şmeler. 1. Bask ı. Ankara: Akademisyen Kitabevi; 2020. p.167-76.
  • 50. Letelier P, Encina N, Morales P, Riffo A, Silva H, Riquelme I, et al. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem. 2021;40(2):115-28. [Crossref] [PubMed] [PMC]
  • 51. Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PRM. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front Im- munol. 2022;13:857573. [Crossref] [PubMed] [PMC]
  • 52. Schneider M. The role of biomarkers in hospitalized COVID-19 patients with systemic manifestations. Biomark Insights. 2022;17:11772719221108909. [Crossref] [PubMed] [PMC]
  • 53. Chaudhary R, Garg J, Houghton DE, Murad MH, Kondur A, Chaudhary R, et al. Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):388-402. [Crossref] [PubMed] [PMC]
  • 54. Chen CH, Lin SW, Shen CF, Hsieh KS, Cheng CM. Biomarkers during COVID-19: mechanisms of change and implications for patient outcomes. Di- agnostics (Basel). 2022;12(2):509. [Crossref] [PubMed] [PMC]
  • 55. Polat T, Dağlıoğlu G, Görür O,İnal TC. COVID-19 hastalarının tanı, tedavi ve takibinde klinik biyokimya laboratuvarlar ının rolü [The role of clinical bio- chemistry laboratories in the diagnosis, treatment and follow-up of COVID-19 patients]. Arşiv Kaynak Tarama Derg. 2022;31(1):1-9. [Crossref]
APA özcanyıldırım s, Işıtmangil G (2024). A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. , 43 - 52. 10.5336/medsci.2023-97930
Chicago özcanyıldırım sena,Işıtmangil Gülbu A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. (2024): 43 - 52. 10.5336/medsci.2023-97930
MLA özcanyıldırım sena,Işıtmangil Gülbu A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. , 2024, ss.43 - 52. 10.5336/medsci.2023-97930
AMA özcanyıldırım s,Işıtmangil G A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. . 2024; 43 - 52. 10.5336/medsci.2023-97930
Vancouver özcanyıldırım s,Işıtmangil G A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. . 2024; 43 - 52. 10.5336/medsci.2023-97930
IEEE özcanyıldırım s,Işıtmangil G "A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease." , ss.43 - 52, 2024. 10.5336/medsci.2023-97930
ISNAD özcanyıldırım, sena - Işıtmangil, Gülbu. "A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease". (2024), 43-52. https://doi.org/10.5336/medsci.2023-97930
APA özcanyıldırım s, Işıtmangil G (2024). A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. Türkiye Klinikleri Tıp Bilimleri Dergisi, 44(1), 43 - 52. 10.5336/medsci.2023-97930
Chicago özcanyıldırım sena,Işıtmangil Gülbu A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. Türkiye Klinikleri Tıp Bilimleri Dergisi 44, no.1 (2024): 43 - 52. 10.5336/medsci.2023-97930
MLA özcanyıldırım sena,Işıtmangil Gülbu A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. Türkiye Klinikleri Tıp Bilimleri Dergisi, vol.44, no.1, 2024, ss.43 - 52. 10.5336/medsci.2023-97930
AMA özcanyıldırım s,Işıtmangil G A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2024; 44(1): 43 - 52. 10.5336/medsci.2023-97930
Vancouver özcanyıldırım s,Işıtmangil G A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2024; 44(1): 43 - 52. 10.5336/medsci.2023-97930
IEEE özcanyıldırım s,Işıtmangil G "A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease." Türkiye Klinikleri Tıp Bilimleri Dergisi, 44, ss.43 - 52, 2024. 10.5336/medsci.2023-97930
ISNAD özcanyıldırım, sena - Işıtmangil, Gülbu. "A Narrative Review of the Evaluation of Biomarkers in COVID-19 Patients Indicating the Course of the Disease". Türkiye Klinikleri Tıp Bilimleri Dergisi 44/1 (2024), 43-52. https://doi.org/10.5336/medsci.2023-97930